ARTICLE | Product Development
eGenesis $125M C round to support clinical trials of kidney, islet transplants from engineered pigs
CEO Sekhri says goal is to ‘eliminate the waiting list’ for organ transplants
March 3, 2021 2:21 AM UTC
Updated on Mar 3, 2021 at 3:12 PM UTC
eGenesis plans to bring its lead CRISPR-edited pig-to-human kidney and pancreatic islet transplant programs into the clinic and scale GMP production with its untranched $125 million series C financing.
Given the high unmet need for organ transplants, President and CEO Paul Sekhri said the company’s near-term goal is to “create a kind of unlimited supply of allo-looking human-compatible organs to eliminate the waiting list.” Recipients would still require immunosuppression. ...
BCIQ Company Profiles